• 04/2023FDA Clearance

    FDA Clearance for CONNEQT Pulse and Digital Companions.
  • 12/2022Clinichain Agreement

  • 11/2022Award Milestone

    CONNEQT Pulse selected as CES 2023 Innovation Award Honoree
  • 11/2022Blumio Joins CardieX Companies

    CardieX Acquires Wearable Sensor Startup Blumio
  • 06/2022Cardiex Announces CONNEQT Pulse

    The World’s First Customizable Dual Blood Pressure and Arterial Health Monitor
  • 05/2022CONNEQT app gains MDDS classification by FDA

  • 04/2022CONNEQT Files Regulatory Submission

    CONNEQT Companion App
  • 04/2022Lisa Musatto joins the Board

  • 03/2022Ticwatch GTH Pro Smartwatch Launched

    CardieX and Mobvoi Enter the US and Australia Markets with Revolutionary Consumer Heart Heath Monitoring Smartwatch
  • 02/2022CardieX Progresses Philip Morris Sponsored Study

  • 02/2022New clinical trial with Andwin, Syneos and Philip Morris

  • 06/2021Technology Milestone

    ATCOR launches world’s first PPG Sensor Algorithm
  • 06/2021ATCOR Technology Chosen for Yale University Clinical Trial

  • 06/2021CONNECT announces LifeQ collaboration

    CONNEQT Health Wearable Featuring World First Sensor Technology
  • 05/2021New Patent

    New ATCOR Patent Granted for Blood Pressure Measurement
  • 05/2021CONNEQT Launch

    New health tech company to compete with Apple and Fitbit
  • 08/2020Expansion of Bayer Clinical Trial Contract

  • 07/2020New Investor Placement

    CardieX Successfully Completes Placement to New Investors
  • 04/2020Major Milestone in Development

    Major Milestone Development of Wearable Sensor Technology
  • 04/2020PPG-based Algorithm Milestone

  • 11/2019New China Distributor

  • 10/2019Deborah Study Complete

  • 05/2019Blumio & CardieX Present Data at IEEE

    Blumio & CardieX present successful results from Macquarie University trial @ IEEE

  • 05/2019CardieX China Established

    CardieX establishes local operations in China with presence in Shanghai and Beijing

  • 04/2019New Oscar 2 Approved in China

    Oscar 2 with SphygmoCor® Inside receives China FDA approval

  • 04/2019inHealth to use ATCOR Technology in Landmark Trial

    inHealth to launch world's first trial cardiovascular program with ATCOR's SphygmoCor® technology

  • 03/2019New China & Product Strategies

    CardieX announces new strategies for next-generation product development and China market expansion

  • 03/2019Expansion of Bayer Contract

    ATCOR expands Bayer contract to provide clinical trial support for major multinational heart failure drug trial

  • 12/2018CardieX & Blumio JDA

    CardieX signs JDA with Blumio for wearable BP sensor development

  • 12/2018Growth Capital Raised

    $5.5M successfully raised in oversubscribed fundraising round

  • 06/2018Growth Capital Raised

    ~5M capital raising to support new growth initiatives
    (with ~30% participation from Directors/C2 Ventures)

  • 05/2018New Corporate Identity: CardieX

    AtCor Medical changes name to CardieX - ASX:CDX.

  • 05/2018AtCor Announces Wearables Trial

    AtCor Medical announces wearable monitor trial in strategic partnerships with Blumio and Macquarie University

  • 03/2018Investment in Blumio

    Investment in innovative Bay Area startup focused on next-generation wearable BP sensor

  • 03/2017A New Way Forward

    New management, strategy, and Board transition to refocus on core technology and new markets

  • 03/2016New Oscar 2 Approved in US

    Oscar 2 with SphygmoCor® Inside receives FDA clearance

  • 01/2015 CPT Code Approval in US

    AMA and CMS approved introduction of CPT code 93050 for arterial pressure waveform analysis

  • 01/2014SphygmoCor® XCEL Approved in China

    China Food & Drug Administration (CFDA) approval granted for newest SphygmoCor® system

  • 11/2012SphygmoCor® XCEL Approved in US

    FDA clearance granted for newest SphygmoCor® system

  • 07/2008SphygmoCor® CvMS Gains CE Mark

    Second generation SphygmoCor® system receives CE Mark

  • 08/2007SphygmoCor® CvMS Approved in US

    FDA clearance granted for second generation SphygmoCor® system

  • 11/2005 IPO on ASX

    AtCor Medical IPOs on ASX - ASX:ACG

  • 04/2004US Division Established

    AtCor Medical, Inc. formed in the US.

  • 2002SphygmoCor® Mx Approval in US

    FDA clearance granted for first generation SphygmoCor® system

  • 2000SphygmoCor® Mx Gains CE Mark

    First generation SphygmoCor® system receives CE Mark

  • 1996SphygmoCor® Approval in Australia

    First generation SphygmoCor® system receives TGA approval

  • 1994ATCOR Medical is Born

    Company founded by Dr. Michael O'Rourke - international leader in the field of cardiovascular physiology and medicine